Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amnion membrane powder is a cell-free biologic wound healing product developed by the Wake Forest Institute for Regenerative Medicine (WFIRM) for the treatment of burns and skin wounds. The product is composed of lyophilized (freeze-dried), gamma irradiation-sterilized fragments of human amniotic membrane derived from the placental amnion. It is designed for topical application to accelerate wound healing and promote skin regeneration by providing a biological scaffold and retaining essential nutrients, growth factors, and proteins. The technology was exclusively licensed to XCell Biologix in 2017 for commercialization in severe burn care and chronic wound markets. A Phase 1 clinical trial (NCT03754218) has evaluated its safety and efficacy for donor site wound healing in patients requiring skin grafts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amnion membrane powder.